spironolactone has been researched along with Canine Diseases in 20 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 9.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| " Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8 mg/kg/d." | 7.01 | Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). ( Atkins, CE; Blondel, T; Coffman, M; Feng, S; Garelli-Paar, C; Guillot, E; Heartsill, S, 2021) |
| "Spironolactone was well tolerated when combined with conventional heart failure treatment." | 6.76 | Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. ( Clercx, C; McEntee, K; Schuller, S; Van Israël, N; Vanbelle, S, 2011) |
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 5.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| " A maximal possible effect (E(max)) model was employed to determine the basic pharmacodynamic parameters of spironolactone, measured by high-performance liquid chromatography, in antagonizing the renal effects of aldosterone." | 5.36 | A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. ( Elliott, J; Guyonnet, J; Kaltsatos, V, 2010) |
| "For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "To determine if the administration of an angiotensin-converting enzyme inhibitor (ACEI) plus spironolactone caused hyperkalemia, hypermagnesemia, or hyponatremia in elderly small dogs with degenerative mitral valve disease (MVD)." | 3.74 | Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease. ( Calvert, CA; Fallaw, TK; Rockwell, JE; Thomason, JD, 2007) |
| " Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8 mg/kg/d." | 3.01 | Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). ( Atkins, CE; Blondel, T; Coffman, M; Feng, S; Garelli-Paar, C; Guillot, E; Heartsill, S, 2021) |
| "Spironolactone was well tolerated when combined with conventional heart failure treatment." | 2.76 | Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. ( Clercx, C; McEntee, K; Schuller, S; Van Israël, N; Vanbelle, S, 2011) |
| "cardiac death or death for other causes)." | 1.62 | Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021) |
| " Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs." | 1.56 | Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. ( Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020) |
| " A maximal possible effect (E(max)) model was employed to determine the basic pharmacodynamic parameters of spironolactone, measured by high-performance liquid chromatography, in antagonizing the renal effects of aldosterone." | 1.36 | A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. ( Elliott, J; Guyonnet, J; Kaltsatos, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 8 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagardi, M | 3 |
| Palermo, V | 1 |
| Locatelli, C | 4 |
| Colombo, FM | 1 |
| Pazzagli, L | 1 |
| Brambilla, PG | 3 |
| Franchini, A | 1 |
| Borgarelli, M | 2 |
| Abbott, JA | 1 |
| Menciotti, G | 1 |
| Crosara, S | 2 |
| Häggström, J | 1 |
| Lahmers, S | 1 |
| Rosenthal, S | 1 |
| Tyrrell, W | 1 |
| Adin, D | 1 |
| Kurtz, K | 1 |
| Atkins, C | 1 |
| Papich, MG | 1 |
| Vaden, S | 1 |
| Ferasin, L | 1 |
| Lamb, K | 1 |
| Bussadori, C | 1 |
| Chiavegato, D | 1 |
| D'Agnolo, G | 1 |
| Migliorini, F | 1 |
| Poggi, M | 1 |
| Santilli, RA | 1 |
| Guillot, E | 3 |
| Garelli-Paar, C | 2 |
| Toschi Corneliani, R | 1 |
| Farina, F | 1 |
| Zani, A | 1 |
| Dirven, M | 1 |
| Smets, P | 1 |
| Guglielmini, C | 1 |
| Oliveira, P | 1 |
| Di Marcello, M | 1 |
| Porciello, F | 1 |
| Ciaramella, P | 1 |
| Piantedosi, D | 1 |
| Smith, S | 1 |
| Vannini, S | 1 |
| Dall'Aglio, E | 1 |
| Savarino, P | 1 |
| Quintavalla, C | 1 |
| Patteson, M | 1 |
| Silva, J | 1 |
| Baron Toaldo, M | 1 |
| Galizzi, A | 2 |
| Stranieri, A | 1 |
| Zanaboni, AM | 1 |
| Malchiodi, D | 2 |
| Borromeo, V | 1 |
| Zanaboni, A | 1 |
| Coffman, M | 1 |
| Blondel, T | 1 |
| Feng, S | 1 |
| Heartsill, S | 1 |
| Atkins, CE | 1 |
| Laskary, A | 1 |
| Fonfara, S | 1 |
| Chambers, H | 1 |
| O'Sullivan, ML | 1 |
| Hezzell, MJ | 1 |
| Boswood, A | 1 |
| López-Alvarez, J | 1 |
| Lötter, N | 1 |
| Elliott, J | 3 |
| Beaumier, A | 1 |
| Rush, JE | 1 |
| Yang, VK | 1 |
| Freeman, LM | 1 |
| Thomason, JD | 2 |
| Rapoport, G | 1 |
| Fallaw, T | 1 |
| Calvert, CA | 2 |
| Chanoit, G | 1 |
| Bublot, I | 1 |
| Viguier, E | 1 |
| Ovaert, P | 1 |
| Bernay, F | 1 |
| Bardon, T | 1 |
| Guyonnet, J | 1 |
| Kaltsatos, V | 1 |
| Schuller, S | 1 |
| Van Israël, N | 1 |
| Vanbelle, S | 1 |
| Clercx, C | 1 |
| McEntee, K | 1 |
| Rockwell, JE | 1 |
| Fallaw, TK | 1 |
| Jeunesse, E | 1 |
| Woehrle, F | 1 |
| Schneider, M | 1 |
| Lefebvre, HP | 1 |
| Broadfoot, F | 1 |
| McGuire, P | 1 |
| Whitehead, M | 1 |
| Watson, P | 1 |
1 review available for spironolactone and Canine Diseases
| Article | Year |
|---|---|
Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular System; Dog Diseases; Dogs; Eplerenone; Heart Fail | 2010 |
5 trials available for spironolactone and Canine Diseases
| Article | Year |
|---|---|
DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Echocardiograph | 2020 |
Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
Topics: Animals; Benzazepines; Dog Diseases; Dogs; Heart Failure; Mitral Valve; Spironolactone; Treatment Ou | 2021 |
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal | 2022 |
Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
Topics: Animals; Dog Diseases; Dogs; Female; Heart Valve Diseases; Male; Mitral Valve; Pilot Projects; Prosp | 2017 |
Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs | 2011 |
14 other studies available for spironolactone and Canine Diseases
| Article | Year |
|---|---|
Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
Topics: Animals; Dog Diseases; Dogs; Furosemide; Humans; Mitral Valve; Pyridazines; Retrospective Studies; S | 2022 |
The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Heart Valve Diseases; Mitral Valve; | 2022 |
Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear | 2020 |
Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
Topics: Aldosterone; Animals; Creatinine; Dog Diseases; Dogs; Female; Furosemide; Heart Valve Diseases; Male | 2021 |
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female | 2021 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
The influence of enalapril and spironolactone on electrolyte concentrations in Doberman pinschers with dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dilated; Cohort Studies; Dog Dise | 2014 |
Transient tricuspid valve regurgitation following surgical treatment of cor triatriatum dexter in a dog.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cor Triatriatum; Diuretics; Dog Dis | 2009 |
A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog.
Topics: Animals; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Heart Failure; Hyperaldosteronism; Ma | 2010 |
Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Drug Interactions; | 2007 |
Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
Topics: Animals; Chromatography, High Pressure Liquid; Cross-Over Studies; Diuresis; Diuretics; Dog Diseases | 2007 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Heart Failure; Humans; Spironolactone | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |